Miltefosine in children with visceral leishmaniasis

Utpal Kant Singh1, Rajniti Prasad, Ranjeet Kumar

  • 1Department of Pediatrics, Nalanda Medical College, Patna 800 020, India. patna@mapra.com

Indian Pediatrics
|January 5, 2007
PubMed

Insights

Miltefosine effectively treats visceral leishmaniasis in children, achieving high cure rates with manageable gastrointestinal side effects. Relapses and side effects like elevated ALT were observed but generally resolved.

Area of Science:

  • Pediatric Infectious Diseases
  • Parasitology
  • Clinical Pharmacology

Background:

  • Visceral leishmaniasis (kala-azar) is a serious parasitic disease affecting children.
  • Effective and safe treatment options for pediatric visceral leishmaniasis are crucial.

Purpose of the Study:

  • To evaluate the efficacy and safety of Miltefosine in children with visceral leishmaniasis.
  • To compare treatment outcomes in children with and without prior antileishmanial drug exposure.

Main Methods:

  • A study involving 64 children diagnosed with visceral leishmaniasis.
  • Patients were divided into two groups: treatment-naïve (Group I) and previously treated (Group II).
  • All patients received oral Miltefosine, with follow-up for clinical response, splenic size, and parasite density.

Main Results:

  • High parasitological cure rates were observed: 93.2% in Group I and 95% in Group II.
  • Gastrointestinal side effects (diarrhea, vomiting) and pancytopenia were common.
  • Transiently elevated ALT levels were noted in a significant proportion of patients, particularly in Group I.

Conclusions:

  • Miltefosine is an effective treatment for pediatric visceral leishmaniasis, regardless of prior treatment history.
  • Close monitoring for side effects like GI disturbances and elevated ALT is recommended.
  • Further research into managing relapses and long-term outcomes is warranted.

Related Concept Videos

Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Leishmaniasis01:30

Leishmaniasis

Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Rocky Mountain Spotted Fever01:26

Rocky Mountain Spotted Fever

Rocky Mountain Spotted Fever (RMSF) is a severe tick-borne illness caused by Rickettsia rickettsii, a Gram-negative, coccobacillary bacterium. This pathogen is an obligate intracellular parasite, requiring a host cell for replication. Transmission occurs through the bite of an infected tick. In the United States, the most important vectors are Dermacentor variabilis (American dog tick) and Dermacentor andersoni (Rocky Mountain wood tick), though other tick species may also serve as vectors.
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...